Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Danish Headache Center
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04592952CT.gov Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab | — | Unknown | — | — | — |
NCT04452929CT.gov The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Calcitonin Gene-Related Peptide 1 (this asset) | Danish Headache Center | Approved | B · 59 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Eptinezumab | Stanford University | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Calcitonin Gene-Related Peptide 1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Without Aura | — | N/A | D · 30 |
| Migraine With Aura | — | N/A | D · 30 |
| Familial Hemiplegic Migraine | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Calcitonin Gene-Related Peptide 1 in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/calcitonin-gene-related-peptide-1-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →